Overview

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety and effectiveness of adjuvant chemoradiation therapy in high-risk breast cancer patients who had received neoadjuvant chemotherapy before their lumpectomy and/or mastectomy and were found to have residual disease. As well as examine the effects of this treatment combination on the immune system.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Virginia
Treatments:
Ado-Trastuzumab Emtansine
Capecitabine
Trastuzumab